DK2901341T3 - Identifikation af tumorbeskyttelsesepitoper til behandling af cancere - Google Patents
Identifikation af tumorbeskyttelsesepitoper til behandling af cancere Download PDFInfo
- Publication number
- DK2901341T3 DK2901341T3 DK13840946.1T DK13840946T DK2901341T3 DK 2901341 T3 DK2901341 T3 DK 2901341T3 DK 13840946 T DK13840946 T DK 13840946T DK 2901341 T3 DK2901341 T3 DK 2901341T3
- Authority
- DK
- Denmark
- Prior art keywords
- epitopes
- identification
- cancer treatment
- tumor protection
- tumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707295P | 2012-09-28 | 2012-09-28 | |
| PCT/US2013/062100 WO2014052707A2 (en) | 2012-09-28 | 2013-09-27 | Identification of tumor-protective epitopes for the treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2901341T3 true DK2901341T3 (da) | 2019-07-15 |
Family
ID=50389139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13840946.1T DK2901341T3 (da) | 2012-09-28 | 2013-09-27 | Identifikation af tumorbeskyttelsesepitoper til behandling af cancere |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10501801B2 (da) |
| EP (1) | EP2901341B1 (da) |
| JP (2) | JP6501708B2 (da) |
| AU (2) | AU2013323368B2 (da) |
| DK (1) | DK2901341T3 (da) |
| ES (1) | ES2737757T3 (da) |
| HR (1) | HRP20191182T1 (da) |
| LT (1) | LT2901341T (da) |
| WO (1) | WO2014052707A2 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501801B2 (en) | 2012-09-28 | 2019-12-10 | University Of Connecticut | Identification of tumor-protective epitopes for the treatment of cancers |
| CN105358708B (zh) * | 2013-03-14 | 2024-07-16 | 儿童医学中心公司 | Cd36鉴定癌症对象以用于治疗的用途 |
| US9990715B2 (en) | 2014-04-04 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Radiotherapy targeted to promote a systemic abscopal effect |
| WO2016040110A1 (en) | 2014-09-10 | 2016-03-17 | The University Of Connecticut | Identification of immunologically protective neo-epitopes for the treatment of cancers |
| US11338026B2 (en) | 2014-09-10 | 2022-05-24 | The University Of Connecticut | Identification of immunologically protective neo-epitopes for the treatment of cancers |
| MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| CA2988388C (en) * | 2015-04-23 | 2022-11-22 | Nantomics, Llc | Cancer neoepitopes |
| SG10201912485PA (en) | 2015-05-13 | 2020-02-27 | Agenus Inc | Vaccines for treatment and prevention of cancer |
| EP3302574A4 (en) * | 2015-05-26 | 2018-10-17 | Advaxis, Inc. | Personalized delivery vector-based immunotherapy and uses thereof |
| EP3323070B1 (en) * | 2015-07-14 | 2024-05-08 | Personal Genome Diagnostics Inc. | Neoantigen analysis |
| US20180237861A1 (en) * | 2015-08-13 | 2018-08-23 | Champions Oncology, Inc. | Personalized treatment of diseases and disorders |
| CA3003251A1 (en) | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors |
| AU2016339022B2 (en) | 2015-10-12 | 2020-09-10 | Nantomics, Llc | Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| EP3431595A4 (en) * | 2016-03-15 | 2019-11-20 | Repertoire Genesis Incorporation | MONITORING AND DIAGNOSIS FOR IMMUNOTHERAPY AND DESIGN FOR THERAPEUTICS |
| JP7197481B2 (ja) | 2016-11-30 | 2022-12-27 | アドバクシス, インコーポレイテッド | 反復性がん突然変異を標的とする免疫原性組成物およびその使用の方法 |
| US12072337B2 (en) | 2017-05-30 | 2024-08-27 | Nant Holdings Ip, Llc | Circulating tumor cell enrichment using neoepitopes |
| MA52363A (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
| US11920202B2 (en) | 2020-04-09 | 2024-03-05 | University Of Connecticut | Unbiased identification of tumor rejection mediating neoepitopes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1522594A3 (en) * | 2003-10-06 | 2005-06-22 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| US8140270B2 (en) * | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| BR112012029066A2 (pt) * | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| HRP20211595T1 (hr) * | 2011-05-24 | 2022-01-21 | BioNTech SE | Individualizirana cjepiva protiv raka |
| US10501801B2 (en) | 2012-09-28 | 2019-12-10 | University Of Connecticut | Identification of tumor-protective epitopes for the treatment of cancers |
-
2013
- 2013-09-27 US US14/431,093 patent/US10501801B2/en active Active
- 2013-09-27 LT LTEP13840946.1T patent/LT2901341T/lt unknown
- 2013-09-27 WO PCT/US2013/062100 patent/WO2014052707A2/en not_active Ceased
- 2013-09-27 ES ES13840946T patent/ES2737757T3/es active Active
- 2013-09-27 EP EP13840946.1A patent/EP2901341B1/en not_active Not-in-force
- 2013-09-27 JP JP2015534719A patent/JP6501708B2/ja not_active Expired - Fee Related
- 2013-09-27 AU AU2013323368A patent/AU2013323368B2/en not_active Ceased
- 2013-09-27 HR HRP20191182TT patent/HRP20191182T1/hr unknown
- 2013-09-27 DK DK13840946.1T patent/DK2901341T3/da active
-
2019
- 2019-01-10 JP JP2019002924A patent/JP2019058190A/ja active Pending
- 2019-06-20 AU AU2019204354A patent/AU2019204354A1/en not_active Abandoned
- 2019-09-23 US US16/578,937 patent/US20200017922A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019058190A (ja) | 2019-04-18 |
| EP2901341A4 (en) | 2016-10-05 |
| EP2901341B1 (en) | 2019-04-10 |
| US20150252427A1 (en) | 2015-09-10 |
| AU2019204354A1 (en) | 2019-07-11 |
| LT2901341T (lt) | 2019-09-25 |
| US20200017922A1 (en) | 2020-01-16 |
| AU2013323368A1 (en) | 2015-04-09 |
| ES2737757T3 (es) | 2020-01-15 |
| EP2901341A2 (en) | 2015-08-05 |
| HRP20191182T1 (hr) | 2019-10-04 |
| JP6501708B2 (ja) | 2019-04-17 |
| US10501801B2 (en) | 2019-12-10 |
| WO2014052707A2 (en) | 2014-04-03 |
| WO2014052707A3 (en) | 2015-05-14 |
| JP2015533082A (ja) | 2015-11-19 |
| AU2013323368B2 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2901341T3 (da) | Identifikation af tumorbeskyttelsesepitoper til behandling af cancere | |
| IL289300A (en) | Combination therapy for treating cancer | |
| IL288181A (en) | Cancer treatment methods | |
| DK2897620T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3033086T3 (da) | Kombinationsterapi til behandling af cancer | |
| DK2818482T3 (da) | Farmaceutisk sammensætning til behandling af cancer | |
| DK2824114T3 (da) | Farmaceutisk sammensætning til behandling af cancer | |
| DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
| DK2900061T3 (da) | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling | |
| DK3046583T3 (da) | Viruslignende partikelkonjugater til behandling af tumorer | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK2717941T3 (da) | Behandling af cancer | |
| HUE048876T2 (hu) | Rákos megbetegedések kezelése | |
| PL2739153T3 (pl) | Leczenie raka sutka | |
| DK2785349T3 (da) | Kombinationsbehandling af cancer | |
| HUE045314T2 (hu) | Kombinációs terápia rák kezelésére | |
| KR102104197B9 (ko) | 난소암의 치료를 위한 항혈관신생 요법 | |
| DK3305285T3 (da) | Anti-androgener til behandlingen af ikke-metastatisk kastrationsresistent prostatakræft | |
| EP3967315C0 (en) | AKKERMANSIA MUCINIPHILA FOR THE TREATMENT OF CANCER | |
| DK3077544T3 (da) | Rationelt-baseret design af en målrettet terapi til cancer | |
| DK3511004T3 (da) | Kombineret præparat til behandling af cancer | |
| DK2825558T3 (da) | Kombinationsterapi til behandling af ovariecancer | |
| DK3290035T3 (da) | Procaspase-kombinationsterapi til behandling af cancer | |
| DK2892535T3 (da) | Fremgangsmåde til adjuverende cancerbehandling | |
| DK2802351T3 (da) | Midler til behandling af triple-negativ brystkræft |